Trieu Vuong 4

What Happened
Dr. Trieu Vuong, a reported 10% owner of Oncotelic Therapeutics, received an award of 4,426 shares of Series A Convertible Preferred Stock on January 22, 2026. The shares were issued as compensation (no cash paid) under a Restricted Stock Agreement tied to the accomplishment of performance milestones; the grant is reported at $0.00. Each preferred share is convertible at the holder's option into common stock on a one-for-one thousand basis, meaning the 4,426 preferred shares would be equivalent to 4,426,000 common shares if converted.

Key Details

• Transaction date: 2026-01-22 (reported on Form 4 filed 2026-01-26)
• Transaction type/code: Grant / Award (A) of Series A Convertible Preferred Stock
• Amount: 4,426 preferred shares; reported acquisition cost $0.00
• Conversion: 1 preferred share = 1,000 common shares (potential common equivalent = 4,426,000) [Footnote F1]
• Reason: Issued as compensation upon achievement of performance milestones under a Restricted Stock Agreement dated January 21, 2026 [Footnote F2]
• Beneficial ownership after transaction: Not specified in the provided summary — see the full Form 4 for total post-transaction holdings
• Timeliness: Filed within the typical 2 business-day window (filed 2026-01-26 for a 2026-01-22 transaction)

Context
This was a compensatory award of convertible preferred stock, not an open-market purchase or sale. Convertible preferred shares give the holder the option to convert into a large number of common shares, which can be dilutive if conversion occurs. Awards tied to performance milestones are common for management/insider compensation and do not, by themselves, signal a buy or sell decision by the market. For exact holdings, potential dilution, and additional filing details, review the full Form 4 (Accession No. 0001493152-26-003634).